Targeted therapy with other BCR::ABL1 TKIs

A randomized prospective study of 846 patients compared nilotinib with imatinib.[15][Level of evidence B3]

A randomized prospective study of 846 patients compared nilotinib with imatinib.[15][Level of evidence B3]

The rate of MMR at 24 months was 71% and 67% for patients who received two-dose schedules of nilotinib and 44% for patients who received imatinib (P < .0001 for both comparisons).

A randomized prospective study of 846 patients compared nilotinib with imatinib.[15][Level of evidence B3]

Progression to accelerated-phase CML or blast crisis occurred in 17 patients who received imatinib (14%), but this progression only occurred in two patients who received nilotinib 300 mg twice daily (<1%, P = .0003) and in five patients who received nilotinib 400 mg twice daily (1.8%, P = .0089).

A randomized prospective study of 519 patients compared dasatinib with imatinib, with the following results:[16][Level of evidence B3]

A randomized prospective study of 519 patients compared dasatinib with imatinib, with the following results:[16][Level of evidence B3]

The rate of MMR at 12 months was 46% for patients who received dasatinib and 28% for patients who received imatinib (P < .0001).

A randomized prospective study of 519 patients compared dasatinib with imatinib, with the following results:[16][Level of evidence B3]

The rate of MMR at 24 months was 64% for patients who received dasatinib and 46% for patients who received imatinib (P < .0001).

A randomized prospective study of 519 patients compared dasatinib with imatinib, with the following results:[16][Level of evidence B3]

At 5 years, there was no difference in PFS or OS.

A randomized prospective study of 519 patients compared dasatinib with imatinib, with the following results:[16][Level of evidence B3]

Progression to accelerated-phase CML or blast crisis occurred in 13 patients (5%) who received imatinib and in six patients (2.3%) who received dasatinib (not statistically significant).

A randomized prospective study of 519 patients compared dasatinib with imatinib, with the following results:[16][Level of evidence B3]

In retrospective comparative analyses, a dasatinib dose of 50 mg a day showed equal efficacy to 100 mg, but resulted in fewer pleural effusions (5% vs. 21%).[17][Level of evidence C3]

A randomized prospective study of 536 patients compared bosutinib with imatinib.[18][Level of evidence B3]

A randomized prospective study of 536 patients compared bosutinib with imatinib.[18][Level of evidence B3]

The MMR rate at 5 years was 73.9% for patients in the bosutinib arm versus 64.6% for patients in the imatinib arm (hazard ratio [HR], 1.57; 95% CI, 1.08–2.28; P = .0075). At 5 years, a DMR (4.5 logs) was attained by 47.4% of patients in the bosutinib arm and 36.6% of patients in the imatinib arm (HR, 1.57; 95% CI, 1.11–2.22).[18]

A randomized prospective study of 536 patients compared bosutinib with imatinib.[18][Level of evidence B3]

Progression to accelerated-phase CML or blast crisis occurred in four patients (1.6%) who received bosutinib and in six patients (2.5%) who received imatinib.